Rita Gerivaz

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study

Manuel Neves, Rita Gerivaz, Graça Esteves, Rui Bergantim et autres

Background Multiple myeloma (MM) is an incurable hematologic malignancy, and even though the complete response (CR) rate has been growing, a high percentage of patients continues to relapse. Recent research showed that most relapses may be related to the persistence of measurable …

pt (code pays fourni par la source)

Predicting Caregiver Burden in Multiple Myeloma: Insights from the Carmma Study Using Machine Learning Models

Carlos da Silva Costa, Adriana Roque, João Santinha, Manuel Neves et autres

Introduction Multiple Myeloma (MM) has a significant impact on the quality of life (QoL) of patients and is associated with psychological, physical, social and financial stress on caregivers. Our previous work showed that older age, poor fitness, advanced disease stage and a …

pt (code pays fourni par la source)

Dithiothreitol-based protein equalisation in the context of multiple myeloma: Enhancing proteomic analysis and therapeutic insights

Inês F. Domingos, Luís B. Carvalho, Carlos Lodeiro, Rita Gerivaz et autres

In this study, we employed the dithiothreitol-based protein equalisation technique and analytical proteomics to better understand myeloma diseases by comparing the proteomes of pellets and supernatants formed upon application of DTT on serum samples. The number of unique proteins found in pellets …

pt, il, it, us (code pays fourni par la source)

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma

Catarina Geraldes, Adriana Roque, Ana Bela Sarmento‐Ribeiro, Manuel Neves et autres

Multiple myeloma (MM) is a very heterogeneous disease with multiple symptoms and clinical manifestations. MM affects mainly elderly patients and is difficult to manage in the presence of comorbidities, polypharmacy, frailty and adverse events of disease-targeted drugs. The rapid changes in MM …

pt (code pays fourni par la source)

Assessment of Multiple Myeloma-Related Burden on Caregivers - a Portuguese National Study

Carlos BT Costa, Manuel Neves, Adriana Roque, Ana Bela Sarmento‐Ribeiro et autres

Introduction Multiple Myeloma (MM) is an incurable hematological cancer that decreases the quality of life of patients but also that of their providers. The disease course is linked with psychological stress of caregivers, but the data on the association between MM characteristics, …

pt (code pays fourni par la source)

P-078 MRDeep study: measurable residual disease rates in patients with multiple myeloma who achieved complete response in 2nd or 3rd lines of treatment

Manuel Neves, Rita Gerivaz, Graça Esteves, Rui Bergatim et autres

Recomendações do Grupo Português do Mieloma Múltiplo para Tratamento do Mieloma Múltiplo

Cristina João, Rui Bergantim, Joana Santos, Celina Afonso et autres

The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in recent years and the attention given to the characteristics of patients have …

pt, cu, ar (code pays fourni par la source)

Engraftment Syndrome (ES) After Autologous Stem Cell Transplantation (SCT): Analysis Of Diagnostic Criteria and Risk Factors

Rita Gerivaz, Fátima Costa, Juliana Schuh, Luis P Monteiro et autres

Abstract ES is increasingly recognized as an important complication of autologous SCT. There is no consensus over diagnostic criteria (leading to variations in reported incidence from 7 to 55%) nor over risk factors. In order to better characterize this syndrome and its …

pt (code pays fourni par la source)